# Reunion Neuroscience

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/reunion-neuroscience

- Industry: Biotechnology
- Headquarters: Toronto, Canada
- Website: www.reunionneuro.com
- Total disclosed funding: $103M
- Latest round: Series A (May 2, 2024)
- Investors on record: 7

## About

Founded in 2022 and based in Ontario, Canada, Reunion Neuroscience Inc., operates as a clinical-stage biopharmaceutical company that develops and patents therapeutic solutions for the mental health industry. In May 2023, MPM Capital agreed to acquire Reunion Neuroscience Inc. for USD 13.1 million in cash or USD 1.12 per share in a public-to-private transaction. As of 2023, the company is led by its president and CEO, Greg Mayes, and is listed on NASDAQ under the ticker symbol REUN.

The company offers various pharmaceutical solutions that include novel psychedelic compounds used for the treatment of psychiatric conditions, including depression. The serotonergic psychedelic compound is used to generate serotonergic receptors in the brain, regulating mood, appetite, sleep, learning, memory, and many other biological and physiological functions, hence acting as an antidepressant for patients.

The company plans to get delisted from the NASDAQ stock exchange.

## Funding rounds

- Series A, May 2, 2024, $103M — Novo Holdings, MPM BioImpact, Plaisance Capital, Arkin Capital, Mitsui & Co. Global Strategic Studies Institute, FemHealth Ventures, Palo Santo Venture Fund

## Investors

- Novo Holdings — Series A
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series A
- Plaisance Capital — Series A
- Arkin Capital (https://capitalatlas.ai/funds/arkin-capital) — Series A
- Mitsui & Co. Global Strategic Studies Institute — Series A
- FemHealth Ventures (https://capitalatlas.ai/funds/femhealth-ventures) — Series A
- Palo Santo Venture Fund (https://capitalatlas.ai/funds/palo-santo-venture-fund) — Series A